Business

GlaxoSmithKline research chief in new role

11 April 2012

GlaxoSmithKline today reshuffled its senior management to give more power to pharmaceuticals research and development head Dr Moncef Slaoui.

Chief executive Andrew Witty's lieutenant will also be taking on responsibility for running GSK's large and growing vaccines business as current vaccines chief Jean Stephenne approaches retirement. Slaoui will get a $100,000 pay rise to $975,000.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT

Retirement
Vaccines